Skip to content
The Nexus
HEALTHJun 23 · 13:06 UTCSTAT NEWSElaine Chen

STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program

Eli Lilly and the FDA have allowed one person to receive the company's obesity drug retatrutide through the FDA's 'compassionate use' program. The access was granted via an exclusive report by Lizzy Lawrence.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Eli LillyorganizationFDAorganizationretatrutidetopiccompassionate use programtopicLizzy Lawrenceperson
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting